Hydroxychloroquine for SLE in children and adolescents

Hydroxychloroquine is usually the first-line drug recommended for all children and adolescents with SLE, unless contraindicated. Hydroxychloroquine has a role in reducing disease flare and hyperlipidaemia. For more detail on the roles of hydroxychloroquine in SLE, see Hydroxychloroquine for SLE in adults.

For children and adolescents (aged 1 month to 18 years) with SLE, use:

For additional considerations specific to hydroxychloroquine use, see Specific considerations for use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).